Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Krister Kristianson"'
Publikováno v:
Health Informatics Journal. 15:305-319
The use of clinical data from electronic medical records (EMRs) for clinical research and for evaluation of quality of care requires an extraction process. Many efforts have failed because the extracted data seemed to be unstructured, incomplete and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::370ed91c2f8747d289ceb6c073a51c1c
https://doi.org/10.1177/1460458209345889
https://doi.org/10.1177/1460458209345889
Publikováno v:
Acta Ophthalmologica. 66:463-466
The effects of topical timolol vs betaxolol on cardiopulmonary exercise performance were studied in a randomised double-masked fashion in 12 healthy male volunteers. Cardiopulmonary parameters were evaluated at the anaerobic threshold and at peak exe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33e20b0f5c646b42d9f5b6cd4a7dc574
https://doi.org/10.1111/j.1755-3768.1988.tb04041.x
https://doi.org/10.1111/j.1755-3768.1988.tb04041.x
Autor:
Jonathan M. Edelman, Steven M. Snapinn, Ole Lederballe-Pedersen, Suzanne Oparil, Hans Ibsen, Björn Dahlöf, Stevo Julius, Frej Fyhrquist, Sverre E. Kjeldsen, Richard B. Devereux, Krister Kristianson, Andreas Moan, Lars H Lindholm, Ulf de Faire, Markku S. Nieminen, Per Omvik, Hans Wedel, Eigil Fossum
Publikováno v:
Journal of the American College of Cardiology. 46:770-775
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin : the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c6e2579d0234bd95e71976474e34298
https://doi.org/10.1016/j.jacc.2005.05.060
https://doi.org/10.1016/j.jacc.2005.05.060
Autor:
Aud Høieggen, Michael H. Alderman, Sverre E. Kjeldsen, Stevo Julius, Richard B. Devereux, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristianson, Ole Lederballe-Pedersen, Lars H. Lindholm, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Cong Chen, Björn Dahlöf, null for the LIFE Study Group
Publikováno v:
Kidney International. 65:1041-1049
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.BackgroundThe Losartan Intervention For Endpoint reduction in hypertension (LIFE) study demonstrated the superiority of a losartan-based regimen over atenolol-based regimen fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be960c2781afa918452aa58bf42e09c
https://doi.org/10.1111/j.1523-1755.2004.00484.x
https://doi.org/10.1111/j.1523-1755.2004.00484.x
Autor:
Sverre E. Kjeldsen, Ulf de Faire, Steven M. Snapinn, Richard B. Devereux, Gareth Beevers, Suzanne Oparil, Katherine E. Harris, Markku S. Nieminen, Per Omvik, Gilbert W. Gleim, Stevo Julius, Ole Lederballe-Pedersen, Lars H Lindholm, Frej Fyhrquist, Björn Dahlöf, Jonathan M. Edelman, Krister Kristianson, Hans Ibsen
Publikováno v:
Seminars in Cerebrovascular Diseases and Stroke. 3:165-170
LIFE was a multinational cardiovascular event outcomes study that assigned 9,193 patients with hypertension and electrocardiographic evidence of left ventricular hypertrophy to randomized, double-blind treatment with a regimen based on either losatan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34115bb33aac4e276c2765d56c0f997c
https://doi.org/10.1053/j.scds.2003.00.028
https://doi.org/10.1053/j.scds.2003.00.028
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Autor:
Kristian Wachtell, Richard B. Devereux, Steven M. Snapinn, Björn Dahlöf, Frej Fyhrquist, Per Omvik, Jonathan M. Edelman, Suzanne Oparil, Stevo Julius, Lars H Lindholm, Sverre E. Kjeldsen, Ole Lederballe-Pedersen, Peter Aurup, Krister Kristianson, Ulf de Faire, Markku S. Nieminen, Michael H. Olsen, Gareth Beevers, Knut Borch-Johnsen, Hans Ibsen, Hans Wedel
Publikováno v:
Lindholm, L H, Ibsen, H, Borch-Johansen, K, Olesen, M H, Wachtell, K, Dahlöf, B, Devereaux, R B, Beevers, G, de Faire, U, Fyhrquist, F, Julius, S, Kjeldsen, S, Kristianson, K, Lederballe-Pedersen, O, Nieminen, M S, Omvik, P, Oparil, S, Wedel, H, Aurup, P, Edelman, J M & Snapinn, S 2002, ' Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study ' J Hypertension, pp. 1879-1886 .
There has been uncertainty about the risk of new-onset diabetes in hypertensive individuals treated with different blood pressure-decreasing drugs.To study this risk in hypertensive individuals who were at risk of developing diabetes mellitus in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057ccf698a9f2a09d44d28245e867fb9
https://doi.org/10.1097/00004872-200209000-00035
https://doi.org/10.1097/00004872-200209000-00035
Autor:
Hans Wedel, Sverre E. Kjeldsen, Ole Lederballe-Pedersen, Björn Dahlöf, Krister Kristianson, Suzanne Oparil, Markku S. Nieminen, Lars H Lindholm, Per Omvik, Frej Fyhrquist, Hans Ibsen, Richard B. Devereux, Stevo Julius, Ulf de Faire
Publikováno v:
American Journal of Hypertension. 13:899-906
The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c985773d5efcd931d25d924c6fe0598b
https://doi.org/10.1016/s0895-7061(00)00280-6
https://doi.org/10.1016/s0895-7061(00)00280-6
Autor:
RB Devereux, Björn Dahlöf, Gareth Beevers, Markku S. Nieminen, Ole Lederballe-Pedersen, S E Kjeldsen, H Wedel, H Ibsen, Thomas Hedner, Frej Fyhrquist, Stevo Julius, Krister Kristianson, L. H. Lindholm, Per Omvik, U de Faire, Suzanne Oparil
Publikováno v:
Hypertension. 32:989-997
Abstract —Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9549b78a9964952d8e1ee9a2dc02ed87
https://doi.org/10.1161/01.hyp.32.6.989
https://doi.org/10.1161/01.hyp.32.6.989
Autor:
Lars L, Gustafsson, Björn, Wettermark, Mats, Kalin, Seher, Korkmaz, Marie E, Persson, Henrik, Almkvist, Paul, Hjemdahl, Margaretha, Julander, Krister, Kristianson, Bo, Ringertz, Gunilla Thörnwall, Bergendahl, Nils, Wiking
Publikováno v:
Lakartidningen. 106(1-2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::45133c7cc9f2bde0a87f740324bbbef2
https://pubmed.ncbi.nlm.nih.gov/19235324
https://pubmed.ncbi.nlm.nih.gov/19235324
Autor:
Stefan D. Anker, Kenneth Dickstein, Margaret James, Linn M.A. Kennedy, Thomas J. Cook, Ronnie Willenheimer, Krister Kristianson
Publikováno v:
European heart journal. 27(23)
Aims To examine the prognostic importance of weight-change in patients with coronary artery disease (CAD), especially following acute myocardial infarction (AMI). Methods and results In 4360 AMI patients (OPTIMAAL trial) without baseline oedema, we a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e31e764099eaf923f9000eab66cecf8
https://pubmed.ncbi.nlm.nih.gov/16891382
https://pubmed.ncbi.nlm.nih.gov/16891382